You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

~ Buy the NESINA (alogliptin benzoate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR NESINA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for NESINA

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00856284 ↗	Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus	Completed	Takeda	Phase 3	2009-03-01	The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
NCT01664624 ↗	Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes	Completed	AstraZeneca	Phase 1	2012-07-01	The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
NCT01664624 ↗	Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes	Completed	Takeda	Phase 1	2012-07-01	The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
NCT01945216 ↗	Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"	Completed	Takeda		2010-07-08	The purpose of this study is to determine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. In addition, examining the safety and efficacy of alogliptin in patients with renal impairment, information on the appropriate dosage of alogliptin according to the severity of impaired renal function should be collected.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for NESINA

Condition Name

Chart
Table

Condition Name for NESINA
Intervention	Trials
Type 2 Diabetes Mellitus	5
Diabetes Mellitus, Type 2	4
Surveillance	3
Type 2 Diabetes	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for NESINA
Intervention	Trials
Diabetes Mellitus, Type 2	14
Diabetes Mellitus	14
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for NESINA

Trials by Country

Map
Table

Trials by Country for NESINA
Location	Trials
United States	57
Mexico	9
Israel	9
Hungary	8
Brazil	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for NESINA
Location	Trials
Florida	3
California	3
Virginia	2
Texas	2
Tennessee	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for NESINA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for NESINA
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	2
Phase 1	1
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for NESINA
Clinical Trial Phase	Trials
Completed	11
Terminated	1
Withdrawn	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NESINA

Sponsor Name

Chart
Table

Sponsor Name for NESINA
Sponsor	Trials
Takeda	12
Kun-Ho Yoon	2
Sanofi	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for NESINA
Sponsor	Trials
Industry	15
Other	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.